Germany-based biotech company SRTD Biotech has closed a €31.5 million seed funding round. At the heart of its approach is an RNA technology designed to address a fundamental challenge facing many RNA-based therapies: How can the activity of a therapeutic molecule be restricted to specific cells without unnecessarily harming healthy tissue?
British biotech Neobe Therapeutics has raised $6.8 million (€6.1 million) in seed funding to develop engineered bacteria that break down the physical barriers preventing cancer drugs and immune cells from reaching solid tumors. The financing will support the preclinical development of its lead program, NEO22, toward a planned regulatory filing in 2028.
University of Oxford spinout Alethio Therapeutics has raised $90 million (about €80 million) to take its G6B-targeting antibody ATX-011 into clinical trials for essential thrombocythemia. The proceeds will fund ATX-011 through Phase 1/2a studies, with the goal of preparing it for Phase 3 development, while advancing additional programs toward applications to begin clinical trials.
Undecimal Bio has launched with $18 million (about €16 million) in seed funding to develop delivery molecules that carry gene-silencing medicines beyond the liver, initially targeting kidney and vascular tissues.
Finnish biotech Desentum has raised €28 million in an oversubscribed equity round to advance three allergy immunotherapy programs, with Phase 2 results for its lead birch pollen candidate expected before year-end.
Oxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that makes mRNA in living cells, targeting manufacturing costs and unwanted immune activation that can limit its use in treatments beyond vaccines.
France’s WhiteLab Genomics has raised $26 million (€23 million) in Series B financing to expand experimental validation of its AI-designed gene delivery technologies and build a portfolio of assets it can own and license.